Read the Market Summary Here @- Global Cardiac Resynchronization Therapy (CRT) Devices Market Size Booming at Healthy CAGR of 8.4% to Touch USD 11.6 Billion by 2030 Global Cardiac Resynchronization ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

Life-saving defibrillators could be installed in town centre streets in Blackpool as part of proposals for new communication hubs. The devices, which are used to resuscitate people who have suffered a ...

According to Coherent Market Insights, the global cardiac pacemaker market is estimated to be valued at USD 4,907.2 million ... This system offers better patient outcomes by reducing complications and ...

The primary outcome of our study was 30‐day in‐hospital mortality following septal reduction therapies. Secondary outcomes included permanent pacemaker or implantable cardioverter‐defibrillator ...

Dual-chamber pacemaker: Has two leads connected to both the right atrium and right ventricle, helping to coordinate the timing between the top and bottom chambers. Implantable ...

Boston Scientific Corporation (NYSE ... which received FDA approval in the quarter and our EMPOWUR leadless pacemaker, which ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...